MarketCap
Facebook
X
Telegram
Ultragenyx Pharmaceutical Income Statement 2025-2011 | RARE
Brief overview of income trends at Ultragenyx Pharmaceutical
The overview follows changes across a five-year period. According to figures from Ultragenyx Pharmaceutical, revenue changed from $271 million to $673 million over five years. The total change was +148.3%, with a CAGR of approximately 19.9%. The pace indicates confident and sustained business growth.
EBITDA changed from −318 million dollars to −500 million dollars (−57.3%). Operating performance weakened relative to revenue. EBITDA margin was −117.3% at the start and −74.3% at the end. The company improved its ability to convert sales into EBITDA.
Across the five years, the net result shifted from −187 million dollars to −575 million dollars. Larger losses indicate rising pressure on the business.
The market value of the business moved from $8.4 billion to $2 billion, or −76.1%. The market is not yet fully reflecting the fundamental progress.
Conclusion
The results contain several connected negative signals. Key strengths include an improving EBITDA margin and revenue expansion. The weaker side of the profile includes a weaker final result, a narrow EBITDA buffer and a weaker market valuation. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Ultragenyx Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.01 B | 3.98 B | 3.53 B | 2.45 B | 5.7 B | 8.42 B | 2.42 B | 2.16 B | 1.97 B | 2.68 B | 2.07 B | 1.67 B | - | - | - |
Shares |
98.6 M | 90.5 M | 73.5 M | 69.9 M | 67.8 M | 60.8 M | 56.6 M | 49.8 M | 42.5 M | 39.6 M | 36.8 M | 28.8 M | - | - | - |
Historical Prices |
20.4 | 44 | 48 | 35 | 84.1 | 138 | 42.7 | 43.5 | 46.4 | 70.3 | 112 | 43.9 | - | - | - |
Net Income |
-575 M | -569 M | -607 M | -707 M | -454 M | -187 M | -403 M | -198 M | -302 M | -246 M | -146 M | -59.8 M | -35.1 M | -16.3 M | -6.85 M |
Revenue |
673 M | 560 M | 434 M | 363 M | 351 M | 271 M | 104 M | 51.5 M | 2.61 M | 133 K | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 1.15 M | 1 K | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 265 M | 94.7 M | 50.3 M | 2.61 M | - | - | - | - | - | - |
Operating Income |
-535 M | -536 M | -569 M | -649 M | -382 M | -330 M | -424 M | -371 M | -329 M | -248 M | -148 M | -56.8 M | -32.3 M | -16 M | - |
Interest Expense |
1 M | -3.96 M | -337 K | -1.57 M | -1.69 M | 607 K | -787 K | -5.59 M | 6.53 M | -1.62 M | -200 K | -3.63 M | -3.01 M | -350 K | - |
EBITDA |
-500 M | -500 M | -543 M | -631 M | -368 M | -318 M | -416 M | -352 M | -323 M | -245 M | -146 M | -56.1 M | -34.6 M | -16 M | -6.54 M |
Operating Expenses |
- | - | - | - | - | 595 M | 519 M | 422 M | 332 M | 248 M | 148 M | 56.8 M | - | - | - |
General and Administrative Expenses |
349 M | 321 M | 310 M | 278 M | 220 M | 183 M | 162 M | 128 M | 99.9 M | 64.9 M | 33 M | 10.8 M | 4.45 M | 3.34 M | 1.84 M |
All numbers in USD currency
Quarterly Income Statement Ultragenyx Pharmaceutical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
99.8 M | 98.5 M | 96.3 M | 92.5 M | 95.5 M | 86.6 M | 84.3 M | 82.3 M | 71.7 M | 70.9 M | 70.4 M | 70.2 M | 70.1 M | 69.9 M | 69.5 M | 69.3 M | 67.9 M | 67.6 M | 67.1 M | 66.8 M | 60.8 M | 60 M | 59.5 M | 57.8 M | 57.7 M | 57.5 M | 53.2 M | 50.9 M | 50.3 M | 49.8 M | 48.2 M | 44.2 M | 42.5 M | 42.3 M | 41.8 M | 41.2 M | 39.6 M | 39 M | 39 M | 38.9 M | 38.3 M | 35.9 M | 34 M | 31.9 M | 31.6 M | 30.1 M | 21.6 M | 3.77 M | 3.62 M | 3.5 M | 3.46 M | - | - | - | - | - | - | - | - |
Net Income |
-180 M | -115 M | -151 M | - | -134 M | -132 M | -171 M | - | -160 M | -160 M | -164 M | - | -245 M | -158 M | -152 M | - | -73 M | -122 M | -136 M | -24 M | -68.8 M | 25.3 M | -119 M | -93.8 M | -113 M | -99.2 M | -96.8 M | -87.8 M | -87.3 M | -52.7 M | 30.3 M | -81.7 M | -79.2 M | -72.9 M | -68.3 M | -71.3 M | -64.9 M | -56.9 M | -52.8 M | -55.2 M | -39.2 M | -29.8 M | -21.4 M | -16.7 M | -15.8 M | -13.6 M | -13.6 M | -11.3 M | -8.43 M | -8.59 M | -6.74 M | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.9 M | - | 81.6 M | 87 M | 99.4 M | 91.5 M | 81.5 M | 61.7 M | 36.3 M | 35.6 M | 25.8 M | 24.1 M | 18.2 M | 16.3 M | 11.8 M | 12.8 M | 10.7 M | 2.41 M | 198 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 766 K | 452 K | - | 273 K | 141 K | 225 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-171 M | -108 M | -143 M | - | -132 M | -116 M | -165 M | - | -145 M | -148 M | -154 M | - | -225 M | -142 M | -137 M | - | -89.8 M | -82.8 M | -107 M | - | -50.3 M | -63.1 M | -121 M | - | -118 M | -112 M | -99.2 M | - | -89.6 M | -94.9 M | -96.5 M | - | -83.7 M | -78.4 M | -70 M | - | -65.8 M | -58.1 M | -53.6 M | - | -39.9 M | -30.1 M | -21.5 M | - | -15.8 M | -13.7 M | -10.3 M | - | -7.76 M | -8.25 M | -6.75 M | - | - | - | - | - | - | - | - |
Interest Expense |
-1.04 M | 2.14 M | 837 K | - | 3.08 M | -1.83 M | -1.6 M | - | -699 K | -1.99 M | 308 K | - | -1.1 M | -930 K | 289 K | - | -415 K | -67 K | -795 K | - | 547 K | 217 K | -456 K | - | -153 K | -376 K | -412 K | - | -147 K | -496 K | -4.96 M | - | 3.37 M | 4.41 M | 582 K | - | -46 K | 159 K | -119 K | - | 31 K | -101 K | -150 K | - | -185 K | -73 K | -3.38 M | - | -735 K | -343 K | 12 K | - | - | - | - | - | - | - | - |
EBITDA |
- | - | -134 M | - | - | - | -157 M | - | - | - | -149 M | - | -225 M | -142 M | -133 M | - | -89.8 M | -82.8 M | -103 M | - | -41.2 M | -57 M | -118 M | - | -112 M | -108 M | -97.1 M | - | -73.1 M | -82.7 M | -90.3 M | - | -80.4 M | -76.2 M | -68.8 M | - | -63.5 M | -56.8 M | -53.1 M | - | -39 M | -29.7 M | -21.3 M | - | -15.4 M | -13.4 M | -10.2 M | - | -7.43 M | -8.02 M | -6.62 M | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 170 M | 206 M | 188 M | 132 M | 125 M | 157 M | 130 M | 144 M | 137 M | 117 M | 107 M | 101 M | 108 M | 107 M | 99.2 M | 83.9 M | 78.4 M | 70 M | 70.6 M | 65.9 M | 58.1 M | 53.6 M | 56.2 M | 39.9 M | 30.1 M | 21.5 M | 16.9 M | 15.8 M | 13.7 M | 10.3 M | 9.52 M | 7.76 M | 8.25 M | 6.75 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.3 M | - | 53.9 M | 53.4 M | 53.3 M | - | 42.1 M | 42.3 M | 47.5 M | - | 41 M | 39.8 M | 38.8 M | - | 31.1 M | 30.7 M | 31.4 M | - | 23.5 M | 20 M | 18.7 M | - | 17.2 M | 14.7 M | 13.2 M | - | 10.2 M | 7.04 M | 4.14 M | - | 2.98 M | 2.42 M | 1.99 M | - | 999 K | 1.05 M | 1.08 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Ultragenyx Pharmaceutical (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands
